638 related articles for article (PubMed ID: 28192720)
21. Dendritic cells in cancer immunology and immunotherapy.
Wculek SK; Cueto FJ; Mujal AM; Melero I; Krummel MF; Sancho D
Nat Rev Immunol; 2020 Jan; 20(1):7-24. PubMed ID: 31467405
[TBL] [Abstract][Full Text] [Related]
22. Between biology and medicine: perspectives on the use of dendritic cells in anticancer therapy.
Szczygieł A; Pajtasz-Piasecka E
Postepy Hig Med Dosw (Online); 2017 Nov; 71(0):921-941. PubMed ID: 29176007
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy.
Zhu S; Yang N; Wu J; Wang X; Wang W; Liu YJ; Chen J
Pharmacol Res; 2020 Sep; 159():104980. PubMed ID: 32504832
[TBL] [Abstract][Full Text] [Related]
24. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
25. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
Netherby CS; Abrams SI
Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell subsets and implications for cancer immunotherapy.
Chen MY; Zhang F; Goedegebuure SP; Gillanders WE
Front Immunol; 2024; 15():1393451. PubMed ID: 38903502
[TBL] [Abstract][Full Text] [Related]
28. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
Foley R; Tozer R; Wan Y
Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number.
Rossowska J; Pajtasz-Piasecka E; Anger N; Wojas-Turek J; Kicielińska J; Piasecki E; Duś D
J Immunother; 2014; 37(9):427-39. PubMed ID: 25304726
[TBL] [Abstract][Full Text] [Related]
30. Deciphering the message broadcast by tumor-infiltrating dendritic cells.
Karthaus N; Torensma R; Tel J
Am J Pathol; 2012 Sep; 181(3):733-42. PubMed ID: 22796439
[TBL] [Abstract][Full Text] [Related]
31. Potential approaches for more successful dendritic cell-based immunotherapy.
Chiang CL; Balint K; Coukos G; Kandalaft LE
Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
[TBL] [Abstract][Full Text] [Related]
32. Plasticity of myeloid-derived suppressor cells in cancer.
Tcyganov E; Mastio J; Chen E; Gabrilovich DI
Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cells in cancer immunotherapy.
Gunzer M; Grabbe S
Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
[TBL] [Abstract][Full Text] [Related]
35. Cancer vaccine by fusions of dendritic and cancer cells.
Koido S; Hara E; Homma S; Namiki Y; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2009; 2009():657369. PubMed ID: 20182533
[TBL] [Abstract][Full Text] [Related]
36. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
37. Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy.
Baniyash M
Cancer Immunol Immunother; 2016 Jul; 65(7):857-67. PubMed ID: 27225641
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
[TBL] [Abstract][Full Text] [Related]
39. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
Saxena M; Bhardwaj N
Trends Cancer; 2018 Feb; 4(2):119-137. PubMed ID: 29458962
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
Chae CS; Teran-Cabanillas E; Cubillos-Ruiz JR
Cancer Immunol Immunother; 2017 Aug; 66(8):969-977. PubMed ID: 28214928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
